Sundrug Co., Ltd.

As of March 31, 2026, Sundrug Co., Ltd. carries a market capitalization of 457.40B, placing it among publicly traded companies globally. Its enterprise value stands at 435.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sundrug Co., Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, Sundrug Co., Ltd. has 116.98M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Sundrug Co., Ltd. maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 23, 2026, Sundrug Co., Ltd.'s stock has declined approximately 13.63% over the past 52 weeks. The 50-day moving average sits at 3,662.58, while the 200-day moving average is 3,867.32.

As of March 31, 2026, Sundrug Co., Ltd. holds 70.52B in cash and equivalents against 48.22B in total debt, resulting in a net debt position of -22.31B. Total book value stands at 286.00B, with working capital of 104.03B providing operational flexibility.

Sundrug Co., Ltd.'s most recent stock split took place on March 29, 2017 with a 1:2 split ratio.